Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts Review
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, May 14, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Bristol-Myers Squibb Company (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2434-100free.
Actavis plc Analyst Notes
On May 12, 2014, Actavis plc (Actavis) announced that it has reached an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya® Gel, 1.2%/2.5%. Under the agreement, Valeant will grant Actavis a license to market its generic Acanya Gel, beginning in July 1, 2018 or earlier under certain circumstances. Actavis informed that it has submitted its Abbreviated New Drug Application (ANDA) for generic Acanya Gel to the U.S. Food and Drug Administration and, if approved, the Company may be entitled 180 days of generic market exclusivity. The full analyst notes on Actavis are available to download free of charge at:
Jazz Pharmaceuticals plc Analyst Notes
On May 8, 2014, Jazz Pharmaceuticals plc (Jazz) released its Q1 2014 financial results. Jazz reported a Q1 2014 net loss attributable to the Company of $92.7 million, or $1.58 per diluted share, compared to net income of $43.4 million, or $0.71 per diluted share, in Q1 2013. The Company informed that Q1 2014 net loss included an upfront license fee and milestone payment of $127.0 million for JZP-110. The adjusted diluted EPS in the quarter increased to $1.61 from $1.37 in Q1 2013. Total revenues during the quarter were $246.92 million, an increase of 25.8% YoY. On average, analysts polled by Reuters expected the Company to report an adjusted diluted EPS of $1.79 on revenues of $254.86 million. Looking ahead, the Company expects full-year 2014 adjusted diluted EPS to be in a range of $8.00-$8.25. The full analyst notes on Jazz Pharmaceuticals are available to download free of charge at:
Bristol-Myers Squibb Company Analyst Notes
On May 6, 2014, Bristol-Myers Squibb Company (Bristol-Myers) announced the retirement of Brian Daniels, Senior Vice President, Global Development and Medical Affairs, effective July 1, 2014. Daniels, who joined Bristol-Myers in 2000, has held his current position since 2008, leading the development of numerous innovative medicines such as Eliquis and Yervoy. "Brian has played a key leadership role in the success of the company's R&D organization and our ability to deliver innovative medicines to patients with serious diseases," said Francis Cuss, Executive Vice President and Chief Scientific Officer, Bristol-Myers. The full analyst notes on Bristol-Myers are available to download free of charge at:
Biogen Idec Inc. Analyst Notes
On May 12, 2014, Biogen Idec Inc. (Biogen) announced the appointment of Richard (Rick) A. Rudick, M.D. as Vice President, Development Sciences, Value-Based Medicine. The Company informed that Dr. Rudick will lead the newly-created Value-Based Medicine Group that will focus on using new technology to develop innovative programs and tools to better understand, measure and manage the treatment of multiple sclerosis. Dr. Rudick will report to Alfred Sandrock, M.D., Ph.D., Group Senior Vice President and Chief Medical Officer. Dr. Rudick joins Biogen Idec from the Cleveland Clinic, where he served as Director of the Mellen Center for Multiple Sclerosis Treatment and Research for nearly 30 years. The full analyst notes on Biogen Idec are available to download free of charge at:
AbbVie Inc. Analyst Notes
On May 8, 2014, AbbVie Inc. (AbbVie) reported the submission of marketing authorization applications (MAAs) to the European Medicines Agency (EMA) seeking approval for the Company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The Company informed that its MAAs are supported by data from the largest all-oral, interferon-free clinical program in GT1 patients conducted to date, which consists of six Phase III studies that include more than 2,300 patients in over 25 countries. "These regulatory submissions bring us closer to offering adult genotype 1 chronic hepatitis C patients an all-oral, interferon-free regimen which has the potential to provide a promising advancement for the hepatitis C community in the European Union," said Scott Brun, M.D., Vice President, Pharmaceutical Development, AbbVie. The full analyst notes on AbbVie are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.